PharmacoEconomics & Outcomes News 475 - 9 Apr 2005

Celecoxib, valdecoxib to gain fromUS FDA recommendations

According to recent research from NOP WorldHealth, new recommendations around COX-2 inhibitorsissued by the US FDA Advisory Committee on 18February this year, will likely lead to gains in prescribingfor both valdecoxib [Bextra] and celecoxib [Celebrex].Physicians and patients are expected to remain wary ofrofecoxib [Vioxx], even if it returns to market.*Physicians anticipate an increase in their valdecoxibprescribing, while rheumatologists, internists andorthopaedic surgeons expect to increase their celecoxibprescribing, says NOP World Health.

Rheumatologists are expected to be more likely thanorthopaedic surgeons to prescribe rofecoxib if itbecomes available again; patients have indicated theywould be unwilling to take rofecoxib if it werereintroduced, while physicians would use it primarily asa second-line treatment.* See PharmacoEconomics & Outcomes News 465: 3, 6 Nov 2004;809041026

NOP World Health. FDA′s COX-2 Recommendations Will Benefit Bextra andCelebrex Though Physicians and Patients Remain Hesitant About Vioxx,According to New NOP World Health Research. Media Release : 23 Mar 2005.Available from: URL: http://www.nopworld.com 809046911

1

PharmacoEconomics & Outcomes News 9 Apr 2005 No. 4751173-5503/10/0475-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved